Answers are grounded in this paper and cite their sources.
Intravenous drug users are the high-risk population of HCV infection with high prevalence and high viral load. Anti-HCV screening for intravenous drug users will have a certain degree of residual risk. Therefore, anti-HCV ELISA screening and nucleic acid detection strategy can accurately diagnose the current infected patients; however, it cannot distinguish the false positive results of antibody screening.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: